Should I buy or sell Dyne Therapeutics stock right now?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last year. There are currently 2 buy rat...
What is Dyne Therapeutics' stock price forecast for 2022?
2 analysts have issued twelve-month price objectives for Dyne Therapeutics' shares. Their forecasts range from $12.00 to $29.00. On average, they e...
How has Dyne Therapeutics' stock performed in 2022?
Dyne Therapeutics' stock was trading at $11.89 on January 1st, 2022. Since then, DYN shares have decreased by 55.9% and is now trading at $5.24. V...
When is Dyne Therapeutics' next earnings date?
Dyne Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Dy...
How were Dyne Therapeutics' earnings last quarter?
Dyne Therapeutics, Inc. (NASDAQ:DYN) posted its earnings results on Monday, May, 2nd. The company reported ($0.69) earnings per share for the quart...
Who are Dyne Therapeutics' key executives?
Dyne Therapeutics' management team includes the following people: Mr. Joshua T. Brumm , CEO, Pres & Director (Age 44, Pay $1.03M) Ms. Susanna Ga...
Who are some of Dyne Therapeutics' key competitors?
Some companies that are related to Dyne Therapeutics include Vectura Group (VEGPF) , Veru (VERU) , Innoviva (INVA) , Mawson Infrastructure Grou...
When did Dyne Therapeutics IPO?
(DYN) raised $175 million in an initial public offering (IPO) on Thursday, September 17th 2020. The company issued 10,300,000 shares at a price of...
What is Dyne Therapeutics' stock symbol?
Dyne Therapeutics trades on the NASDAQ under the ticker symbol "DYN."
Are investors shorting Dynamics Special Purpose?
Dynamics Special Purpose saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 53,300 shares,...
Who are Dynamics Special Purpose's key executives?
Dynamics Special Purpose's management team includes the following people: Dr. Omid C. Farokhzad M.D. , Ph.D., Exec. Chair (Age 53) Dr. Mostafa R...
Who are some of Dynamics Special Purpose's key competitors?
Some companies that are related to Dynamics Special Purpose include Adaptive Biotechnologies (ADPT) , Recursion Pharmaceuticals (RXRX) , Kymera...
When did Dynamics Special Purpose IPO?
(DYNS) raised $200 million in an IPO on Wednesday, May 26th 2021. The company issued 20,000,000 shares at a price of $10.00 per share. J.P. Morgan...
What is Dynamics Special Purpose's stock symbol?
Dynamics Special Purpose trades on the NASDAQ under the ticker symbol "DYNS."
Who are Dynamics Special Purpose's major shareholders?
Dynamics Special Purpose's stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investme...
Which institutional investors are selling Dynamics Special Purpose stock?
DYNS stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., FNY Investment Advisers LLC, and A...
How do I buy shares of Dynamics Special Purpose?
Shares of DYNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBul...
What is Dynamics Special Purpose's stock price today?
One share of DYNS stock can currently be purchased for approximately $9.90.
About Dyne Therapeutics
Dyne Therapeutics (NASDAQ:DYN) Frequently Asked Questions
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.
0.0 Analyst's Opinion
Dyne Therapeutics' stock was trading at $12.81 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, DYN stock has decreased by 37.0% and is now trading at $8.07. View which stocks have been most impacted by COVID-19.
Are investors shorting Dynamics Special Purpose?
Dynamics Special Purpose has received 0 “outperform” votes. (Add your “outperform” vote.)
Who are some of Dynamics Special Purpose's key competitors?
Dynamics Special Purpose saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 126,800 shares, an increase of 137.5% from the December 31st total of 53,400 shares. Based on an average daily volume of 142,700 shares, the short-interest ratio is currently 0.9 days.
What is Dynamics Special Purpose's stock symbol?
Some companies that are related to Dynamics Special Purpose include CONX (CONX), Pontem (PNTM), Apollo Strategic Growth Capital II (APGB), CC Neuberger Principal Holdings II (PRPB), BRC (BRCC), SilverBox Engaged Merger Corp I (SBEA), Brooge Energy (BROG), Paya (PAYA), Elliott Opportunity II (EOCW), SVF Investment (SVFA), Avanti Acquisition (AVAN), Hudson Executive Investment Corp.
Who are Dynamics Special Purpose's major shareholders?
Dynamics Special Purpose trades on the NASDAQ under the ticker symbol "DYNS."
Which institutional investors are selling Dynamics Special Purpose stock?
Dynamics Special Purpose's stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (9.96%), JPMorgan Chase & Co. (5.59%), Taconic Capital Advisors LP (2.11%), Omni Event Management Ltd (1.84%), Millennium Management LLC (1.76%) and Silver Rock Financial LP (1.64%).
Which institutional investors are buying Dynamics Special Purpose stock?
DYNS stock was sold by a variety of institutional investors in the last quarter, including Schonfeld Strategic Advisors LLC, FNY Investment Advisers LLC, Silver Rock Financial LP, and Millennium Management LLC.
What is Dyne Therapeutics?
DYNS stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Taconic Capital Advisors LP, Omni Event Management Ltd, Kingfisher Capital LLC, CSS LLC IL, D. E. Shaw & Co. Inc., ARK Investment Management LLC, and Citadel Advisors LLC.
Does market cap include convertible securities?
Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.
DynTek Joins the Microsoft Intelligent Security Association
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
DynTek Achieves Microsoft Gold Competency in Security
IRVINE, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- DynTek Services, Inc., a leading provider of professional technology solutions, today announced it has joined the Microsoft Intelligent Security Association, an ecosystem of independent software vendors and managed security service providers that have integrated their solutions with Microsoft to increase visibility and better protect against threats.